Risks

High net debt to EBITDA and only mid-single-digit interest coverage leave XRAY more exposed to refinancing and rate pressure than larger, less levered peers.

A 142-day cash conversion cycle, driven by elevated inventory and receivables, ties up working capital and limits flexibility versus faster-turning dental peers.

Current and quick ratios above 1.0 reduce near-term liquidity stress, but they still trail stronger balance-sheet peers that can absorb demand volatility more easily.

Longer inventory and receivables cycles increase the risk of channel destocking or reimbursement delays translating into weaker cash generation than peers with tighter operating discipline.

Opportunities

XRAY’s liquidity ratios above 1.0 provide more operating resilience than highly stretched peers, supporting continuity through softer dental demand periods.

If working capital normalizes, the large inventory and receivables base offers a meaningful cash-release opportunity versus peers with less balance-sheet trapped capital.

Interest coverage remains positive, giving XRAY more room than weaker peers to absorb modest margin pressure while preserving access to capital markets.

Dental end-market exposure can benefit from elective procedure recovery, but XRAY’s upside appears less pronounced than premium-positioned peers with stronger pricing power.

Overall Score

XRAY’s forward positioning is constrained by elevated leverage and working-capital intensity versus peers, while liquidity and positive coverage provide some offset and limited upside.